Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3% – Should You Buy?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s share price shot up 7.3% during trading on Friday . The stock traded as high as $24.84 and last traded at $24.5970. 44,997 shares were traded during mid-day trading, a decline of 54% from the average session volume of 98,160 shares. The stock had previously closed at $22.93.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price target for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $45.00.

Lyell Immunopharma Stock Up 7.2%

The firm has a market cap of $522.08 million, a PE ratio of -1.07 and a beta of -0.13. The firm’s 50 day moving average is $26.30 and its 200-day moving average is $17.62.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. On average, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds and other institutional investors have recently modified their holdings of LYEL. AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the 2nd quarter valued at about $94,000. Bridgeway Capital Management LLC acquired a new position in Lyell Immunopharma during the second quarter worth $159,000. Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the 2nd quarter worth $258,000. Finally, Clarius Group LLC increased its position in Lyell Immunopharma by 4.3% during the third quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock worth $324,000 after acquiring an additional 820 shares during the period. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.